Weight-loss injections have gone from a niche prescription to dinner-table conversation in just a few years. In India, the picture has shifted fast too after semaglutide's patent expired in March 2026, generic versions brought monthly costs down from the ₹8,000–16,000 range to as low as ₹1,300 - 4,500, putting GLP-1 drugs within reach of far more people than ever before.
That accessibility is genuinely good news for many patients with obesity and related comorbidities. But affordability solves only one part of the sustainability question. As someone working in public health nutrition, I think it's worth separating what these drugs do very well from what they were never designed to do and why a balanced diet remains the harder, but more durable, answer.
What the Evidence Actually Shows About Semaglutide
The weight often comes back when the drug stops. This is the most consistent finding across the research. The STEP 1 trial extension found significant regain within a year of stopping semaglutide, and a meta-analysis of GLP-1 receptor agonist trials confirmed the same pattern: most people regain a substantial share of the weight they lost once treatment ends, because the drug was suppressing appetite hormones and energy intakenot changing the underlying behaviours or environment that drove weight gain in the first place. Real-world data is a little more encouraging: some cohort studies show milder regain when patients continue lifestyle changes or switch to a maintenance therapy, but even the most optimistic real-world analyses describe a minority of patients doing this well not the majority sailing through unassisted. The clinical read is essentially: semaglutide functions like a treatment for a chronic condition, similar to blood pressure medication. Stop taking it, and the underlying physiology reasserts itself.
Muscle loss is a genuine, if mixed, concern. Body-composition studies show that a meaningful share of early weight loss on semaglutide comes from lean mass, not just fat — one recent DXA-based study found lean mass dropped in the first seven months before stabilising. Other trials found the proportion of lean-to-fat mass actually improved overall. The honest summary is that outcomes vary a lot by age, protein intake, and whether patients are doing resistance training alongside the drug and without that scaffolding, losing muscle along with fat can quietly undermine metabolic health even as the number on the scale looks like success.
It doesn't touch the root causes. Sedentary work, ultra-processed food environments, poor sleep, occupational stress, family dietary patterns none of this change because appetite is pharmacologically suppressed. The moment the prescription stops (due to cost, side effects, pregnancy planning, supply issues, or simply a clinical decision), the same environment that contributed to weight gain is still there, unchanged.
Long-term safety data is still accumulating. These drugs have only been used at scale for obesity for a few years. Gastrointestinal side effects are common, and researchers are still working out optimal duration, tapering strategies, and who is a genuinely good long-term candidate.
None of this means semaglutide is a bad drug for people with obesity-related diabetes, cardiovascular risk, or severe metabolic disease, it can be genuinely life-changing under medical supervision. But "effective" and "sustainable as a standalone solution" are two different claims, and the evidence is fairly clear that they aren't the same thing here.
Why a Balanced Diet Is the More Durable Foundation
A balanced, culturally appropriate diet works differently not faster, and not as dramatically, but through a mechanism that doesn't disappear when you stop "taking" it.
It builds a skill, not a dependency. Learning to structure meals adequate protein, fibre-rich vegetables, whole grains, controlled portions of refined carbohydrates and fats is a capability that stays with a person. There's no withdrawal effect when the "treatment" is a way of eating you already know how to do.
It improves the whole metabolic picture, not just weight. Dietary pattern change consistently shows benefits for lipid profiles, blood pressure, insulin sensitivity, gut health, and even mental well-being outcomes that matter as much as the number on the scale, especially in the context of dyslipidemia and cardiometabolic risk.
It preserves (and can build) muscle mass, especially when paired with adequate protein intake and physical activity avoiding the lean-mass trade-off that shows up in some pharmacological weight loss.
It's culturally adaptable. A coastal Karnataka thali, a Kannada household's daily meal pattern, or a South Indian vegetarian diet can all be restructured around balance rather than restriction which matters enormously for long-term adherence. Diets that ask people to abandon their food culture rarely stick; diets that work within it do.
It has no recurring cost ceiling. Even at today's lower generic prices, medication is an ongoing monthly expense for as long as it's used. Dietary change, once established, costs nothing extra to maintain.
The trade-off is honesty: diet and lifestyle change is slower, requires sustained effort, and doesn't offer the dramatic early results a weekly injection can. That's precisely why it's often dismissed as "not working" when in fact it's working on a different, more durable timescale.
The Sustainable Answer Isn't Either/Or
The most defensible public health position isn't "medication bad, diet good." It's that medication treats a symptom while diet and lifestyle address the mechanism. For patients with significant obesity-related disease, semaglutide can be a legitimate bridge but the evidence strongly suggests it works best as an adjunct to dietary and behavioural change, not a replacement for it. Used alone, its benefits are tightly bound to continued use; used alongside a rebuilt relationship with food, it has a real chance of leading somewhere permanent.
True sustainability in weight and metabolic health isn't about finding the intervention that produces the fastest drop in weight. It's about finding the one that a person can still be doing, without external input, five or ten years from now. For most people, that answer is still the plate in front of them not the pen in the fridge.
